Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model

Kui Wang, Forrest M. Kievit, Jonathan G. Sham, Mike Jeon, Zachary R. Stephen, Arvind Bakthavatsalam, James O. Park, Miqin Zhang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle-based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP-siRNA-GPC3 Ab) is made of an iron oxide core coated with chitosan-polyethylene glycol (PEG) grafted polyethyleneimine copolymer, which is further functionalized with siRNA and conjugated with a monoclonal antibody (Ab) against human glypican-3 (GPC3) receptor highly expressed in HCC. A rat RH7777 HCC cell line that coexpresses human GPC3 and firefly luciferase (Luc) is established to evaluate the nanovector. The nanoparticle-mediated delivery of siRNA against Luc effectively suppresses Luc expression in vitro without notable cytotoxicity. Significantly, NP-siLuc-GPC3 Ab administered intravenously in an orthotopic model of HCC is able to specifically bound to tumor and induce remarkable inhibition of Luc expression. The findings demonstrate the potential of using this nanovector for targeted delivery of therapeutic siRNA to HCC.

Original languageEnglish (US)
Pages (from-to)477-487
Number of pages11
JournalSmall
Volume12
Issue number4
DOIs
StatePublished - Jan 27 2016

Fingerprint

RNA
Iron oxides
Heterografts
Small Interfering RNA
Tumors
Glypicans
Hepatocellular Carcinoma
Luciferases
Neoplasms
Cytotoxicity
Antibodies
Nanoparticles
Genes
Gene Knockdown Techniques
Firefly Luciferases
Polyethyleneimine
Monoclonal antibodies
Chitosan
ferric oxide
Polyethylene glycols

Keywords

  • RNA interference
  • copolymer polyethyleneimine
  • glypican-3
  • hepatocellular carcinoma
  • nanoparticles

ASJC Scopus subject areas

  • Biotechnology
  • Biomaterials
  • Chemistry(all)
  • Materials Science(all)

Cite this

Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. / Wang, Kui; Kievit, Forrest M.; Sham, Jonathan G.; Jeon, Mike; Stephen, Zachary R.; Bakthavatsalam, Arvind; Park, James O.; Zhang, Miqin.

In: Small, Vol. 12, No. 4, 27.01.2016, p. 477-487.

Research output: Contribution to journalArticle

Wang, K, Kievit, FM, Sham, JG, Jeon, M, Stephen, ZR, Bakthavatsalam, A, Park, JO & Zhang, M 2016, 'Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model', Small, vol. 12, no. 4, pp. 477-487. https://doi.org/10.1002/smll.201501985
Wang, Kui ; Kievit, Forrest M. ; Sham, Jonathan G. ; Jeon, Mike ; Stephen, Zachary R. ; Bakthavatsalam, Arvind ; Park, James O. ; Zhang, Miqin. / Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. In: Small. 2016 ; Vol. 12, No. 4. pp. 477-487.
@article{1a8e82d7e6bd47c2b513b36740dc3c85,
title = "Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model",
abstract = "Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle-based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP-siRNA-GPC3 Ab) is made of an iron oxide core coated with chitosan-polyethylene glycol (PEG) grafted polyethyleneimine copolymer, which is further functionalized with siRNA and conjugated with a monoclonal antibody (Ab) against human glypican-3 (GPC3) receptor highly expressed in HCC. A rat RH7777 HCC cell line that coexpresses human GPC3 and firefly luciferase (Luc) is established to evaluate the nanovector. The nanoparticle-mediated delivery of siRNA against Luc effectively suppresses Luc expression in vitro without notable cytotoxicity. Significantly, NP-siLuc-GPC3 Ab administered intravenously in an orthotopic model of HCC is able to specifically bound to tumor and induce remarkable inhibition of Luc expression. The findings demonstrate the potential of using this nanovector for targeted delivery of therapeutic siRNA to HCC.",
keywords = "RNA interference, copolymer polyethyleneimine, glypican-3, hepatocellular carcinoma, nanoparticles",
author = "Kui Wang and Kievit, {Forrest M.} and Sham, {Jonathan G.} and Mike Jeon and Stephen, {Zachary R.} and Arvind Bakthavatsalam and Park, {James O.} and Miqin Zhang",
year = "2016",
month = "1",
day = "27",
doi = "10.1002/smll.201501985",
language = "English (US)",
volume = "12",
pages = "477--487",
journal = "Small",
issn = "1613-6810",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model

AU - Wang, Kui

AU - Kievit, Forrest M.

AU - Sham, Jonathan G.

AU - Jeon, Mike

AU - Stephen, Zachary R.

AU - Bakthavatsalam, Arvind

AU - Park, James O.

AU - Zhang, Miqin

PY - 2016/1/27

Y1 - 2016/1/27

N2 - Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle-based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP-siRNA-GPC3 Ab) is made of an iron oxide core coated with chitosan-polyethylene glycol (PEG) grafted polyethyleneimine copolymer, which is further functionalized with siRNA and conjugated with a monoclonal antibody (Ab) against human glypican-3 (GPC3) receptor highly expressed in HCC. A rat RH7777 HCC cell line that coexpresses human GPC3 and firefly luciferase (Luc) is established to evaluate the nanovector. The nanoparticle-mediated delivery of siRNA against Luc effectively suppresses Luc expression in vitro without notable cytotoxicity. Significantly, NP-siLuc-GPC3 Ab administered intravenously in an orthotopic model of HCC is able to specifically bound to tumor and induce remarkable inhibition of Luc expression. The findings demonstrate the potential of using this nanovector for targeted delivery of therapeutic siRNA to HCC.

AB - Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle-based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP-siRNA-GPC3 Ab) is made of an iron oxide core coated with chitosan-polyethylene glycol (PEG) grafted polyethyleneimine copolymer, which is further functionalized with siRNA and conjugated with a monoclonal antibody (Ab) against human glypican-3 (GPC3) receptor highly expressed in HCC. A rat RH7777 HCC cell line that coexpresses human GPC3 and firefly luciferase (Luc) is established to evaluate the nanovector. The nanoparticle-mediated delivery of siRNA against Luc effectively suppresses Luc expression in vitro without notable cytotoxicity. Significantly, NP-siLuc-GPC3 Ab administered intravenously in an orthotopic model of HCC is able to specifically bound to tumor and induce remarkable inhibition of Luc expression. The findings demonstrate the potential of using this nanovector for targeted delivery of therapeutic siRNA to HCC.

KW - RNA interference

KW - copolymer polyethyleneimine

KW - glypican-3

KW - hepatocellular carcinoma

KW - nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84955496283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955496283&partnerID=8YFLogxK

U2 - 10.1002/smll.201501985

DO - 10.1002/smll.201501985

M3 - Article

C2 - 26641029

AN - SCOPUS:84955496283

VL - 12

SP - 477

EP - 487

JO - Small

JF - Small

SN - 1613-6810

IS - 4

ER -